Clinical Trials

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Are you an adult who has PAD and overweight or obesity? This study aims to learn whether participating in an exercise program with a weight loss program reduces PAD signs and symptoms more than an exercise program alone. To participate, you must be between 18 and 85 years old, have PAD, and have a body mass index (BMI) greater than 28 but less than 45. Participants must also be willing to use a smartphone and attend weekly study sessions. This study is located in Evanston, Illinois; New Orleans, Louisiana; and Minneapolis, Minnesota.